Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

In the life sciences sector, capital allocation often provides a clearer story than pure drug discovery. Royalty Pharma plc (RPRX) and AstraZeneca PLC (AZN) offer two distinct growth models within this sector. Royalty Pharma utilizes royalties and milestone payments derived from drugs developed by other companies, while AstraZeneca invests heavily in its own drug discovery and development efforts.

Recently, Royalty Pharma acquired a portion of Neurimmune's royalty interest in AstraZeneca's candidate cliramitug, a TTR-fibril-depleting antibody designed to clear existing deposits of transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a fatal condition caused by misfolded protein accumulation in the heart. This move positions Royalty Pharma to benefit from high-reward cash flows if the Phase 3 DepleTTR-CM trial succeeds.

Comparing the financial performance of AstraZeneca and Royalty Pharma reveals some differences. While AstraZeneca continues to grow at scale, with a 6% increase in total revenue in H1 2026 and solid operating leverage, Royalty Pharma's top-line model relies on portfolio receipts, which rose 10% year-over-year in Q1 2026 to $925 million.

Royalty Pharma has deployed significant capital into new deals, with $528 million in Q1 2026 alone, and has announced total transaction value of up to $1.25 billion, including major R&D co-funding agreements.

Both companies face challenges. AstraZeneca must contend with high R&D spending, potential trial failures, and upcoming patent expirations. Royalty Pharma, on the other hand, depends on the commercial performance of its partners and could be negatively impacted by patent expirations, generic competition, or clinical setbacks within partnered pipelines.

Despite these risks, Royalty Pharma's low-overhead, high-margin business model and expanding portfolio of royalty interests across multiple partners make it an attractive growth story for investors.